Skip to product information
1 of 9

CeraVe

Blemish Barrier Patches

Blemish Barrier Patches

★★★★★4.8 (representative, not live review data)

Regular price $2.00 USD
Regular price $9.99 USD Sale price $2.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Quantity

CeraVe Blemish Barrier Patches are the first and only hydrocolloid blemish patches with three essential ceramides plus niacinamide, helping to soothe the skin while immediately reducing the appearance of all types of blemishes upon application. Developed by dermatologists for clinically proven results, this blemish patch formula absorbs oil in as little as 3 hours and helps protect the delicate skin barrier—decreasing the risk of developing post-blemish marks.

Made For: oily, sensitive

Helps With: acne

Key Ingredients: ceramide, niacinamide

View full details
How to Use

Apply to clean, dry skin over the targeted area. Replace as directed and discontinue use if irritation occurs.

Ingredients

Made For

  • CeraVe Blemish Barrier Patches are the first and only hydrocolloid blemish patches with three essential ceramides plus niacinamide, helping to soothe the skin while immediately red
  • Formulated with ceramides to support the skin barrier.
  • Includes niacinamide to help comfort the skin.
  • Suitable for sensitive skin.

Helps With

CeraVe Blemish Barrier Patches are the first and only hydrocolloid blemish patches with three essential ceramides plus niacinamide, helping to soothe the skin while immediately reducing the appearance of all types of blemishes upon application. Developed by dermatologists for clinically proven results, this blemish patch formula absorbs oil in as little as 3 hours and helps protect the delicate skin barrier—decreasing the risk of developing post-blemish marks.

Key Ingredients

  • Ceramide
  • Niacinamide

Reviews

Representative customer feedback

★★★★★

4.8 out of 5 based on representative customer sentiment. Representative only, not live review data.

“Absorbs well and fits easily into a daily routine.”

Representative review, not live data